{"id":333921,"date":"2026-10-30T20:11:59","date_gmt":"2026-10-30T14:41:59","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/indo-us-bio-tech-q2-results-fy27-loss-4-crore\/"},"modified":"2026-10-30T20:11:59","modified_gmt":"2026-10-30T14:41:59","slug":"indo-us-bio-tech-q2-results-fy27-loss-4-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/indo-us-bio-tech-q2-results-fy27-loss-4-crore\/","title":{"rendered":"Indo US Bio-Tech Q2 Results FY27: Profit Slips to a Loss, Revenue Rs 15.05 Cr, PAT Rs -3.67 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Indo US Bio-Tech Q2 Results FY27 were declared on 30 October 2026 on a standalone basis for the July to September 2026 quarter. Revenue fell 51.22% YoY to Rs 15.05 Cr from Rs 30.85 Cr, and the company posted a net loss of Rs 3.67 Cr against a net profit of Rs 3.45 Cr a year earlier. These quarterly results show YoY growth turning negative on both the top line and the bottom line.<\/p>\n<\/div>\n

Indo US Bio-Tech Ltd<\/a> (INDOUS) Q2 Results FY27 announced on 30 October 2026, covering the company’s financial performance for the July to September quarter. The results date brought revenue of Rs 15.05 Cr and a PAT loss of Rs 3.67 Cr. Indo US Bio-Tech Q2 Results FY27 are based on standalone results, and revenue is down 51.22% from the same quarter last year.<\/p>\n

Univest has built this results analysis around Indo US Bio-Tech Q2 Results, covering the financial highlights, business drivers, outlook and risks. The financial highlights come first, with revenue, Operating Profit and net profit set against the same quarter last year.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n